One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron, Steve R. Ommen
doi : 10.1161/CIRCULATIONAHA.120.051330
Circulation. 2021 | Volume 143, Issue 12: 1181–1183
Cell-Free DNA to Detect Heart Allograft Acute Rejection
Sean Agbor-Enoh, Palak Shah, Ilker Tunc, Steven Hsu, Stuart Russell, Erika Feller, Keyur Shah, Maria E. Rodrigo, Samer S. Najjar, Hyesik Kong, Mehdi Pirooznia, Ulgen Fideli, Alfiya Bikineyeva, Argit Marishta, Kenneth Bhatti, Yanqin Yang, Cedric Mutebi, Kai Yu, Moon Kyoo Jang, Charles Marboe, Gerald J. Berry, Hannah A. Valantine and For the GRAfT Investigators
doi : 10.1161/CIRCULATIONAHA.120.049098
Circulation. 2021 | Volume 143, Issue 12: 1184–1197
After heart transplantation, endomyocardial biopsy (EMBx) is used to monitor for acute rejection (AR). Unfortunately, EMBx is invasive, and its conventional histological interpretation has limitations. This is a validation study to assess the performance of a sensitive blood biomarker—percent donor-derived cell-free DNA (%ddcfDNA)—for detection of AR in cardiac transplant recipients.
Solid Gold, or Liquid Gold?
Michelle M. Kittleson, Sonia Garg
doi : 10.1161/CIRCULATIONAHA.120.052925
Circulation. 2021 | Volume 143, Issue 12: 1198–1201
Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors
Christoph H?chsmann, James L. Dorling, Corby K. Martin, Robert L. Newton Jr, John W. Apolzan, Candice A. Myers, Kara D. Denstel, Emily F. Mire, William D. Johnson, Dachuan Zhang, Connie L. Arnold, Terry C. Davis, Vivian Fonseca, Carl J. Lavie, Eboni G. Price-Haywood, Peter T. Katzmarzyk and For the PROPEL Research Group
doi : 10.1161/CIRCULATIONAHA.120.051328
Circulation. 2021 | Volume 143, Issue 12: 1202–1214
Intensive lifestyle interventions (ILIs) are the first-line approach to effectively treat obesity and manage associated cardiometabolic risk factors. Because few people have access to ILIs in academic health centers, primary care must implement similar approaches for a meaningful effect on obesity and cardiometabolic disease prevalence. To date, however, effective lifestyle-based obesity treatment in primary care is limited. We examined the effectiveness of a pragmatic ILI for weight loss delivered in primary care among a racially diverse, low-income population with obesity for improving cardiometabolic risk factors over 24 months.
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention
Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger, Alexander Parkhomenko, M. Cecilia Bahit, Stephan Windecker, Ronald Aronson, Otavio Berwanger, Sigrun Halvorsen, Suzanne de Waha-Thiele, Peter Sinnaeve, Harald Darius, Robert F. Storey, Renato D. Lopes
doi : 10.1161/CIRCULATIONAHA.120.051020
Circulation. 2021 | Volume 143, Issue 12: 1215–1223
In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention treated with a P2Y12 inhibitor. We evaluated the risk-benefit balance of antithrombotic therapy according to kidney function.
Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects
Wenzhu Li, Chase W. Kessinger, Makoto Orii, Hang Lee, Lang Wang, Ido Weinberg, Michael R. Jaff, Guy L. Reed, Peter Libby, Ahmed Tawakol, Peter K. Henke, Farouc A. Jaffer
doi : 10.1161/CIRCULATIONAHA.120.049096
Circulation. 2021 | Volume 143, Issue 12: 1224–1238
Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution.
The Open Vein Hypothesis and Postthrombotic Syndrome
Aaron W. Aday, Joshua A. Beckman
doi : 10.1161/CIRCULATIONAHA.120.052451
Circulation. 2021 | Volume 143, Issue 12: 1239–1241
Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction
Njabulo Ngwenyama, Annet Kirabo, Mark Aronovitz, Francisco Vel?zquez, Francisco Carrillo-Salinas, Ane M. Salvador, Tania Nevers, Venkataraman Amarnath, Albert Tai, Robert M. Blanton, David G. Harrison, Pilar Alcaide
doi : 10.1161/CIRCULATIONAHA.120.051889
Circulation. 2021 | Volume 143, Issue 12: 1242–1255
Despite the well-established association between T-cell–mediated inflammation and nonischemic heart failure, the specific mechanisms triggering T-cell activation during the progression of heart failure and the antigens involved are poorly understood. We hypothesized that myocardial oxidative stress induces the formation of isolevuglandin (IsoLG)–modified proteins that function as cardiac neoantigens to elicit CD4+ T-cell receptor (TCR) activation and promote heart failure.
Highlights From the Circulation Family of Journals
doi : 10.1161/CIRCULATIONAHA.121.054326
Circulation. 2021 | Volume 143, Issue 12: 1256–1261
From the Literature
Tracy Hampton
doi : 10.1161/CIRCULATIONAHA.121.054218
Circulation. 2021 | Volume 143, Issue 12: 1262–1263
A Noteworthy Electrocardiogram
Zhaolong Xu, Qinghua Chang, Renguang Liu
doi : 10.1161/CIRCULATIONAHA.120.053436
Circulation. 2021 | Volume 143, Issue 12: 1264–1266
One-Year Outcomes of a Randomized Trial Comparing a Self-Expanding With a Balloon-Expandable Transcatheter Aortic Valve
Won-Keun Kim, Thomas Walther, Christof Burgdorf, Helge M?llmann, Axel Linke, Simon Redwood, Christian Thilo, Michael Hilker, Michael Joner, Holger Thiele, Lars Conzelmann, Lenard Conradi, Sebastian Kerber, Gerhard Schymik, Bernard Prendergast, Oliver Husser, Johannes Blumenstein, Stefan Stortecky, Dik Heg, Arnaud Künzi, Peter Jüni, Stephan Windecker, Thomas Pilgrim, Jonas Lanz and For the SCOPE I Investigators
doi : 10.1161/CIRCULATIONAHA.120.052251
Circulation. 2021 | Volume 143, Issue 12: 1267–1269
Letter by Saleh Regarding Article, “Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin”
Christian Saleh
doi : 10.1161/CIRCULATIONAHA.120.050617
Circulation. 2021 | Volume 143, Issue 12: e790–e791
Correction to: Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association
doi : 10.1161/CIR.0000000000000970
Circulation. 2021 | Volume 143, Issue 12: e792–e793
Correction to: Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T Cell Activation in the Heart and Promote Cardiac Dysfunction
doi : 10.1161/CIR.0000000000000975
Circulation. 2021 | Volume 143, Issue 12: e794
